Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) Invested Capital (2016 - 2025)

Historic Invested Capital for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to $14.1 million.

  • Lipocine's Invested Capital fell 2602.41% to $14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year decrease of 2602.41%. This contributed to the annual value of $21.0 million for FY2024, which is 308.36% up from last year.
  • Lipocine's Invested Capital amounted to $14.1 million in Q3 2025, which was down 2602.41% from $17.1 million recorded in Q2 2025.
  • Over the past 5 years, Lipocine's Invested Capital peaked at $47.2 million during Q4 2021, and registered a low of $14.1 million during Q3 2025.
  • For the 5-year period, Lipocine's Invested Capital averaged around $29.7 million, with its median value being $28.6 million (2023).
  • Per our database at Business Quant, Lipocine's Invested Capital skyrocketed by 45629.57% in 2021 and then plummeted by 4283.86% in 2023.
  • Lipocine's Invested Capital (Quarter) stood at $47.2 million in 2021, then fell by 24.56% to $35.6 million in 2022, then tumbled by 42.84% to $20.4 million in 2023, then rose by 3.08% to $21.0 million in 2024, then crashed by 32.65% to $14.1 million in 2025.
  • Its Invested Capital stands at $14.1 million for Q3 2025, versus $17.1 million for Q2 2025 and $19.2 million for Q1 2025.